about
The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule.Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody moleculeADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers.PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules.Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator.Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6.Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX.Tailored doxorubicin-hyaluronan conjugate as a potent anticancer glyco-drug: an alternative to prodrug approach.Development of a radiolabeled beta-human chorionic gonadotropin.Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m.Cyclic versus Noncyclic Chelating Scaffold for 89Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression.Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label.Influence of Histidine-Containing Tags on the Biodistribution of ADAPT Scaffold Proteins.Molecular design of radiocopper-labelled Affibody molecules.Affibody‑mediated imaging of EGFR expression in prostate cancer using radiocobalt‑labeled DOTA‑ZEGFR:2377Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumoursComparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2Influence of composition of cysteine-containing peptide-based chelators on biodistribution of 99mTc-labeled anti-EGFR affibody molecules.Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with 111In and 68GaComparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenograftsComparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting PropertiesCAIX-targeting radiotracers for hypoxia imaging in head and neck cancer modelsSelection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6Potent and specific fusion toxins consisting of a HER2‑binding, ABD‑derived affinity protein, fused to truncated versions of Pseudomonas exotoxin AOptimal composition and position of histidine-containing tags improves biodistribution of 99mTc-labeled DARPin G3HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo BiodistributionFeasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1Influence of Several Compounds and Drugs on the Renal Uptake of Radiolabeled Affibody Molecules
P50
Q33920975-7DA3DCE6-7D3B-4459-80CA-F7A7D4D7824AQ34775811-E5864BCA-941E-4166-AC1C-A07E8E09ADCEQ35752923-DCC8266F-D4D4-4CE0-9A7E-0BC0A2CB95A8Q36649532-1ECB48B3-6265-4FAE-A8F9-7EAC1911ECF9Q37427038-2C29C624-D197-45FA-9CAF-7DA3AC81FECDQ38741232-D8550D62-D0F9-4F04-BC8E-4C878DA1D584Q38751583-D77AF34E-F804-4B2D-8D70-3E381D7C8920Q39077970-C2D42005-34F5-436B-86A0-447970F45A2DQ43240338-D4E0A2D6-FE7D-432F-A8F4-6C0DC88A9142Q46219345-3CB08DFE-A363-4523-B791-121B88C02D99Q47158578-34885B86-1112-40F3-B770-B73AC1A75C37Q47867757-C37B7F9E-F94C-4890-8997-72096141B667Q53207880-FB014EC0-FFD5-4E3C-9B89-839C27A119DAQ55030086-A3431610-060A-4A27-8478-3ECA1717B94EQ57465002-3265701F-A3E1-479B-9A1C-BDDF143DA189Q58610164-895D230C-3F21-4E60-BB66-B6B5FC579C49Q64254353-0A2AAAA6-AE48-4B83-9BD6-2BF400878107Q64882020-AB980679-0E3B-4C84-9FA2-7A812AE4F4B8Q88981155-760EA3AE-C879-45D0-B7CD-CB2AD610A7B8Q90781815-495221FB-A719-47F1-9967-81ED21097F85Q90878751-0A663BEB-6528-4A0E-8DA7-2B2835CC5614Q91891264-C285F458-9274-4C60-A9BC-0293EF55EB81Q91975932-9729B225-7BF8-401A-BA17-BF57183550D1Q92628666-B8AC12D2-80AE-4B00-A99D-86E14CAD70B8Q93116555-DAE90843-20C0-4CB2-8A06-DBDE159150C4Q94449592-91AADB69-25EB-4001-9EAC-41D02C98AC5EQ94556642-8771AD56-63ED-4BB2-8108-1386164DFEF1Q96294432-44B64CF0-86EE-4784-B7B3-BF6B2CD087D4
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Javad Garousi
@en
Javad Garousi
@nl
type
label
Javad Garousi
@en
Javad Garousi
@nl
prefLabel
Javad Garousi
@en
Javad Garousi
@nl
P31
P496
0000-0002-7224-6304